Health

Mintal Tracker Wins 2023 iF DESIGN AWARD

The award-winning app was recognized as Solution for Sleep Disorders  SUNNYVALE, Calif., May 30, 2023 /PRNewswire/ -- Mintal Tracker, a sleep tracking app driven by artificial intelligence (AI) technology that offers a scientific approach to healthier sleep, was named as a winner of this year's ...

2023-05-30 20:00 2206

Lunit and the Japan National Cancer Center Hospital East Partner in AI Pathology to Advance Precision Oncology

* Collaborative research with Japan's largest oncology practice shows Lunit SCOPE's potential in predicting clinical outcomes for rectal cancer SEOUL, South Korea, May 30, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a global provider of AI-powered cancer diagnostic solutions, today announced c...

2023-05-30 20:00 1986

Inmagene to Participate in the Jefferies Healthcare Conference on June 8

SAN DIEGO, SHANGHAI and SYDNEY, May 30, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), a global clinical-stage biotechnology company focused on developing novel therapeutics for immunology-related diseases, today announced that management has been invited to participate in the ...

2023-05-30 20:00 2185

Immorna Announces First Subject Dosed in a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Vaccine Developed for the Prevention of Shingles

MORRISVILLE, N.C., May 30, 2023 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the first subject has been dosed in the Company's First-In-Human (FIH) Phase 1 multi-center st...

2023-05-30 19:00 1877

ANEW MEDICAL, INC. Enters Into Definitive Merger Agreement with Redwoods Acquisition Corp.

* ANEW MEDICAL, INC. ("ANEW") has entered into a definitive business combination agreement with Redwoods Acquisition Corp. (NASDAQ: RWOD). * ANEW is developing a platform and commercializing novel gene therapies to alleviate and/or reverse the progression of neurogenerative diseases. * ANEW ...

2023-05-30 18:00 2996

iNtRON identifies Prophage and Jamphage in the Pancreatic cancer related Microbiome

* It was confirmed the presence of Prophage and Jamphage in the Alkalihalobacillus clausii * Prophage and Jamphage are expected to play a substantial role in bacterial survival and immune regulation in the body. BOSTON and SEOUL, South Korea, May 29, 2023 /PRNewswire/ -- iNtRON Biotechnology ...

2023-05-30 10:15 1791

Bridge Biotherapeutics to Present at the 2023 BIO International Convention

SEONGNAM, South Korea and CAMBRIDGE, Mass., May 29, 2023 /PRNewswire/ -- Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, is scheduled to give a company presentation onTuesday, June...

2023-05-30 06:00 2188

CELL WORLD - Aiming at Internationalization, Starting from Regulation - The 1st Global Cell Therapy Summit and Hillgene Biopharma Anniversary Celebration Successfully Held

SUZHOU, China, May 29, 2023 /PRNewswire/ -- On May 26, 2023, the "CELL WORLD 1st Global Cell Therapy Summit and Hillgene Biopharma Anniversary Celebration," meticulously planned by Hillgene Biopharma and Biovalley, was successfully held at the DoubleTree by Hilton in Wuzhong District, Suzhou. The...

2023-05-29 20:03 3158

AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer

HIGHLIGHTS * Amplia's highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic cancer * FOLFIRINOX is the most widely used treatment for pancreatic cancer patients in the US,Canada and most European countries * T...

2023-05-29 16:51 2838

Collaborators at the Keio and Osaka Universities Present Key Non-Clinical Data with Stable/Functional-Induced Regulatory T Cells (S/F-iTregs) in Autoimmune Disease Models

OSAKA, Japan, May 29, 2023 /PRNewswire/ -- RegCell collaborators from Keio University and Osaka University presented key data at ISID 2023 Tokyo Satellite Meeting. Their presentation demonstrated that in a murine pemphigus model, S/F-iTregs significantly decreased clinical scores, circulating ant...

2023-05-29 13:21 2074

Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023

* Porustobart in combination of toripalimab showed promising anti-tumor activity * Porustobart in combination of toripalimab showed acceptable safety profile in HCC * Porustobart in combination of toripalimab showed favorable PK/PD signature CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZH...

2023-05-29 09:42 2191

77.4% ORR! Abbisko to present the updated clinical phase Ib data of Pimicotinib (ABSK021) at the 2023 ASCO Annual Meeting

SHANGHAI, May 28, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that the updated results of Phase Ib study of its CSF-1R inhibitor Pimicotinib (ABSK021) in treating patients with advanced tenosynovial giant cell tumor ("TGCT"), will be rele...

2023-05-28 21:00 2945

Pulse Medical receives FDA Breakthrough Device Designation for its μFR® system

SHANGHAI, May 26, 2023 /PRNewswire/ -- Pulse Medical Technology, Inc. (Pulse Medical) 4th generation μFR® system has received an FDA Breakthrough Device designation.  Pulse Medical, founded in 2015, located in Shanghai, China, is dedicated to developing innovative technology for precise diagnosi...

2023-05-26 22:08 3914

E-Home Household Services Holdings Limited Announces Half-Year Results Ended December 31, 2022

FUZHOU, China, May 26, 2023 /PRNewswire/ -- E-Home Household Service Holdings Limited (Nasdaq: EJH) (the "Company" or "E-Home"), a provider of integrated household services inChina, today announced its financial results for the six months endedDecember 31, 2022. Financial Highlight * Total re...

2023-05-26 21:06 5382

ProfoundBio Announces Further Advancement of Lead Programs - PRO1184 (Rinatabart Sesutecan) and PRO1160 in the Clinic

* PRO1160 first patient dosed in the US * China NMPA clearance for PRO1184 (rinatabart sesutecan, Rina-S) and PRO1160 to initiate clinical trials * Rina-S preliminary clinical data is encouraging SUZHOU, China and WOODINVILLE, Wash., May 26, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage...

2023-05-26 20:00 2287

Waterdrop Inc. to Report First Quarter 2023 Financial Results on June 5, 2023

BEIJING, May 26, 2023 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH ) ("Waterdrop" or the "Company"), a leading technology platform de...

2023-05-26 19:30 4295

FivepHusion Announces Strategic Collaboration with Treehill Partners and Syneos Health

Supporting FivepHusion's Global Development and Commercialization Strategy SYDNEY, May 26, 2023 /PRNewswire/ -- FivepHusion, an advanced clinical-stage biotechnology company, today announced its collaboration with Treehill Partners, aNew York-based strategic and financial advisory firm specializi...

2023-05-26 13:42 2206

Ascentage Pharma Presents Updated Results from Multiple Clinical Studies at American Society of Clinical Oncology Annual Conference

SUZHOU, China, and ROCKVILLE, Md., May 25, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that 4 of its abstracts were selected for presenta...

2023-05-26 10:01 3146

Daewoong Pharmaceutical Publishes Molecular Mechanism of Bersiporocin as an Antifibrotic in EMBO Molecular Medicine

* Elucidated molecular mechanism behind safety and efficacy of Bersiporocin * Bersiporocin is currently in Phase II clinical trial for Idiopathic Pulmonary Fibrosis SEOUL, South Korea, May 25, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEOLee Chang-jae and Jeon Sengho) announced on the 25th...

2023-05-26 06:00 2285

Dizal's Oncology Pipeline Continues to Impress with Two Oral Presentations at 2023 ASCO Annual Meeting

SHANGHAI, May 25, 2023 /PRNewswire/ -- Dizal (688192.SH) today announced that data from its oncology portfolio will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting,June 2-6, 2023 in Chicago. The data which include updated analyses of Dizal's two leading assets...

2023-05-26 06:00 2156
1 ... 83848586878889 ... 273